For an extensive review of current tau-targeting therapies for AD, Congdon et al. [78] have meticulously outlined the mechanisms of action for each category of tau-targeting therapy, along with the current clinical trial status of these interventions. This evidence concerns the gene MAPT and Alzheimer disease.